{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-23-000114","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.528317+00:00","generated_at":"2026-06-08T06:08:26.519905+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ClearPoint Neuro Q3 revenue $5.8M (+12% YoY); biologics & drug delivery up 55% to $3.5M","bullets":["Revenue $5.8M, +12% YoY; biologics & drug delivery $3.5M (+55%) driven by preclinical services.","Gross margin 57% vs 71% prior year due to lower-margin preclinical services and facility transition.","Operational cash burn $1.8M, lowest since 2020; cash $24.3M at Sept 30.","FY 2023 revenue guidance narrowed to $23-25M, representing 11-18% growth.","Entered new strategic biologics agreements; submitted three stereotactic products and updated software to FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-23-000114","json":"https://secwatch.observer/filing/0001285550-23-000114.json","markdown":"https://secwatch.observer/filing/0001285550-23-000114.md","text":"https://secwatch.observer/filing/0001285550-23-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000114/0001285550-23-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000114/clpt-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:08:26.519905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"66e64c6a8ec38a8a77c945c5315470dc52b6d3a7","claim":"ClearPoint Neuro, Inc. reported third quarter ended September 30, 2023 results: revenue $5.8 million, net income ($0.34) per diluted share, EPS ($0.34) per diluted share. Guidance reaffirmed.","evidence_excerpt":"navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter Highlights • Reported quarterly revenue of $5.8 million, a 12% year-over-year increase; • Increased biologics and drug delivery revenue to $3.5 million, a 55% year-over-year increase; • Operational cash burn of $1.8 million, the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555023000114/0001285550-23-000114-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$5.8 million"},{"label":"Net income","value":"($0.34) per diluted share"},{"label":"EPS","value":"($0.34) per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}